Company intelligence / Profile preview

MedXCell SA

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

MedXCell SA is a Swiss biotech venture builder focused on developing innovative off-the-shelf cellular immunotherapies that combine allogeneic natural killer cells with monoclonal antibodies. Its lead asset through subsidiary CYTEA BIO targets glioblastoma using umbilical cord blood-derived NK cells armed with high-affinity mAbs. The company operates a venture-building model co-designing early-stage projects with academic partners before spinning out independent ventures. As of mid‑2024, its pipeline remains largely preclinical/non-clinical POC; no published human efficacy data yet available.

Therapeutic areas: Oncology
Modalities: Allogeneic cell therapies (Natural Killer cells)Monoclonal antibodies (mAbs)Off-the-shelf cellular therapies
Industry: Biotech

Partnerships

Collaboration with EFS Besançon PIBT and Bionoveo for cell therapy product development/manufacturingclose relationship with Institute for Regenerative Medicine & Biotherapy at CHU Montpellier University Hospital in France

Beyond the preview

Go deeper on MedXCell SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedXCell SA.

Explore the full profile